HUP0003591A2 - Az oppozíciós ellenálló rendellenesség kezelése - Google Patents

Az oppozíciós ellenálló rendellenesség kezelése

Info

Publication number
HUP0003591A2
HUP0003591A2 HU0003591A HUP0003591A HUP0003591A2 HU P0003591 A2 HUP0003591 A2 HU P0003591A2 HU 0003591 A HU0003591 A HU 0003591A HU P0003591 A HUP0003591 A HU P0003591A HU P0003591 A2 HUP0003591 A2 HU P0003591A2
Authority
HU
Hungary
Prior art keywords
treatment
oppositional
disorder
deflant
reboxetine
Prior art date
Application number
HU0003591A
Other languages
English (en)
Inventor
John Harrison Heiligenstein
Original Assignee
Eli Lilly And Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Co. filed Critical Eli Lilly And Co.
Publication of HUP0003591A2 publication Critical patent/HUP0003591A2/hu
Publication of HUP0003591A3 publication Critical patent/HUP0003591A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A találmány tárgyát egy oppozíciós ellenálló rendellenességként ismertpszichiátriai betegség kezelésére szolgáló eljárás képezi, amelyneksorán valamely, ilyen kezelésre igényt tartó betegnek egy norepinefrinújrafelvételt gátló anyag hatékony mennyiségét adják be, példáultomoxetint, reboxetint, (I) általános képletű vegyületet, ahol Xjelentése alkiltiocsoport, Y jelentése alkilcsoport. Ó
HU0003591A 1997-09-23 1998-09-01 Treatment of oppositional deflant disorder HUP0003591A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5962997P 1997-09-23 1997-09-23
PCT/US1998/018114 WO1999015176A1 (en) 1997-09-23 1998-09-01 Treatment of oppositional defiant disorder

Publications (2)

Publication Number Publication Date
HUP0003591A2 true HUP0003591A2 (hu) 2002-01-28
HUP0003591A3 HUP0003591A3 (en) 2002-02-28

Family

ID=22024203

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003591A HUP0003591A3 (en) 1997-09-23 1998-09-01 Treatment of oppositional deflant disorder

Country Status (17)

Country Link
US (1) US6028070A (hu)
EP (1) EP0919236A1 (hu)
JP (1) JP2001517627A (hu)
KR (1) KR20010024218A (hu)
CN (1) CN1146412C (hu)
AU (1) AU740109B2 (hu)
BR (1) BR9812357A (hu)
CA (1) CA2304115A1 (hu)
EA (1) EA002689B1 (hu)
HU (1) HUP0003591A3 (hu)
IL (1) IL134716A0 (hu)
NO (1) NO20001458L (hu)
NZ (1) NZ502810A (hu)
PL (1) PL339426A1 (hu)
TR (1) TR200000755T2 (hu)
UA (1) UA56257C2 (hu)
WO (1) WO1999015176A1 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1069900E (pt) 1998-04-09 2005-10-31 Pharmacia & Upjohn Co Llc Novos tratamentos para disturbios nervosos
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
DK1493442T3 (da) * 1999-07-01 2005-12-19 Pharmacia & Upjohn Co Llc Reboxetin til behandling af perifer neuropati
DE60035232T2 (de) 1999-07-01 2008-02-14 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
CO5210862A1 (es) * 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
SK12812002A3 (sk) * 2000-03-07 2003-08-05 Eli Lilly And Company Spôsob liečenia psoriázy
US7750030B2 (en) * 2001-03-29 2010-07-06 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US6613763B2 (en) * 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
US20050096395A1 (en) * 2002-02-12 2005-05-05 Rao Srinivas G. Methods of treating attention deficit/hyperactivity disorder (adhd)
EP1485078B1 (en) * 2002-03-15 2012-09-26 Cypress Bioscience, Inc. Milnacipran for the treatment of irritable bowel syndrome
EP1494664A2 (en) * 2002-04-18 2005-01-12 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
WO2003092649A2 (en) * 2002-04-29 2003-11-13 Alza Corporation Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation
KR100779786B1 (ko) * 2002-06-17 2007-11-28 화이자 이탈리아 에스.알.엘. 레복세틴의 제약 염
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
KR101185322B1 (ko) * 2003-02-14 2012-09-21 피에르 파브르 메디카먼트 약제 제조용 밀나시프란의 (1에스,2알) 거울상이성체의용도
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
ATE526954T1 (de) * 2003-07-28 2011-10-15 Leslie Joe Dunaway Atomoxetin zur behandlung von allergischer rhinitis und asthma
AU2004312059A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
EP2496079A4 (en) * 2009-11-06 2014-05-14 Pierre Fabre Médicament Sas NOVEL (1S, 2R) -2- (AMINOMETHYL) -N, N-DIETHYL-1-PHENYLCYCLOPROPANECARBOXAMIDE CRYSTALLINE FORMS
US9737562B2 (en) 2012-12-11 2017-08-22 The Mclean Hospital Corporation Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
EP0537915B1 (en) * 1991-09-27 1995-07-12 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines as norepinephrine inhibitors
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
MX9800589A (es) * 1995-07-24 1998-04-30 Lilly Co Eli Tratamiento de desorden de la falta de atencion/hiperactividad.

Also Published As

Publication number Publication date
HUP0003591A3 (en) 2002-02-28
US6028070A (en) 2000-02-22
EP0919236A1 (en) 1999-06-02
IL134716A0 (en) 2001-04-30
CN1146412C (zh) 2004-04-21
KR20010024218A (ko) 2001-03-26
UA56257C2 (uk) 2003-05-15
NO20001458D0 (no) 2000-03-21
EA002689B1 (ru) 2002-08-29
EA200000349A1 (ru) 2000-10-30
PL339426A1 (en) 2000-12-18
NO20001458L (no) 2000-03-21
JP2001517627A (ja) 2001-10-09
CA2304115A1 (en) 1999-04-01
CN1270520A (zh) 2000-10-18
AU9128298A (en) 1999-04-12
TR200000755T2 (tr) 2000-09-21
NZ502810A (en) 2002-03-01
WO1999015176A1 (en) 1999-04-01
BR9812357A (pt) 2000-09-12
AU740109B2 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
HUP0003591A2 (hu) Az oppozíciós ellenálló rendellenesség kezelése
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
BR0200155A (pt) Tratamento combinado para depressão
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
MXPA02012434A (es) Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
ATE447858T1 (de) Pharmazeutische zusammensetzung für muskelanabolismus
CY1124763T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας
PT1333887E (pt) Metodo de tratamento de desordens musculares
EP1983000A3 (en) Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
BR0213358A (pt) Uso de flibanserina
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
DE69831000D1 (de) Verwendung von cytidin und cytosin-enthaltenden verbindungen zur behandlung von reizmittelgelgebrauch
BR9814923A (pt) Método para tratamento de doença de alzheimer
AP2002002387A0 (en) Method of inhibiting amyloid aggregation and imaging amyloid deposits.
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
DE69935331D1 (de) Verfahren und verbindungen zur behandlung der depression
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
HUP0302732A2 (hu) Érproliferációt gátló gyógyszerészeti készítmények, és eljárás azok alkalmazására
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
WO2000004012A8 (en) COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF
DE60238395D1 (de) Ess-protein und verfahren zur verwendung davon
MY124089A (en) Use of cetirizine for preventing the onset of asthma
AU2058402A (en) Use of lipopeptides or lipoproteins for treating lung infections and lung tumours

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees